CoChat

Deamidation and isomerization liability analysis of 131 clinical-stage antibodies

Open access
Lu, Xiaojun, Nobrega, R. Paul, Lynaugh, Heather, Jain, Tushar, Barlow, Kyle, Boland, Todd, Sivasubramanian, Arvind, Vásquez, Maximiliano, Xu, Yingda · 2019 · mAbs
Cited by 141

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Contemporary in vivo and in vitro discovery platform technologies greatly increase the odds of identifying high-affinity monoclonal antibodies (mAbs) towards essentially any desired biologically relevant epitope. Lagging discovery throughput is the ability to select for highly developable mAbs with drug-like properties early in the process. Upstream consideration of developability metrics should reduce the frequency of failures in later development stages. As the field moves towards incorporating biophysical screening assays in parallel to discovery processes, similar approaches should also be used to ensure robust chemical stability. Optimization of chemical stability in the early stages of discovery has the potential to reduce complications in formulation development and improve the potential for successful liquid formulations. However, at present, our knowledge of the chemical stability characteristics of clinical-stage therapeutic mAbs is fragmented and lacks comprehensive comparative assessment. To address this knowledge gap, we produced 131 mAbs with amino acid sequences corresponding to the variable regions of clinical-stage mAbs, subjected these to low and high pH stresses and identified the resulting modifications at amino acid-level resolution via tryptic peptide mapping. Among this large set of mAbs, relatively high frequencies of asparagine deamidation events were observed in CDRs H2 and L1, while CDRs H3, H2 and L1 contained relatively high frequencies of instances of aspartate isomerization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19420862.2018.1548233

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 141

Metadata

Authors
Lu, X., Nobrega, R. P., Lynaugh, H., Jain, T., Barlow, K., Boland, T., Sivasubramanian, A., Vásquez, M., & Xu, Y.
Venue
mAbs
Published
2018-12-10
Volume
11
Issue
1
Pages
45-57
ISSN
  • 1942-0862 (ISSN-L)
  • 1942-0870
OpenAlex
W2905282967
Cited by
141
References
3
FWCI
3.69
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. https://app.cochat.ai/papers/10.1080/19420862.2018.1548233
The paper
Lu, X., Nobrega, R. P., Lynaugh, H., Jain, T., Barlow, K., Boland, T., Sivasubramanian, A., Vásquez, M., & Xu, Y. (2019). Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. mAbs. https://doi.org/10.1080/19420862.2018.1548233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.